A third (33 per cent) of U.S. employers currently include cell and gene therapies in their benefits plans and 36 per cent are actively evaluating the use of these treatments, according to a new survey by the Integrated Benefits Institute. The survey, which polled more than 400 U.S. employers and more than 200 benefits consultants, […]
The previous year was an interesting one in the world of employee benefits plans. Over the previous 12 months, employers have navigated the explosion of claims for glucagon-like peptide-1 receptor agonist medications like Ozempic, some forward momentum on national pharmacare and some employers changed their approach to diversity, equity and inclusion policies. Here are five […]
From the unlocking of pension benefits in Nova Scotia to new pay transparency rules in Ontario, stories about pension and employment legislation caught the eyes of Benefits Canada’s readers in 2024. In addition, a pair of articles on the rollout of new glucagon-like peptide-1 receptor agonist medications in Canada were also popular with readers. Here […]
The percentage of claimants filing claims for obesity drugs increased by 43 per cent in 2023, according to a new report by GreenShield. The report, which analyzed the insurer’s 2023 claims data, found diabetes medications saw a 13 per cent increase in cost, accounting for nine per cent of total drug costs in 2023. There […]
In Canada, the average health benefits cost trend for 2025 is estimated to be 7.4 per cent, up from five per cent in 2024, according to a new report by Aon. It found the top medical conditions driving health benefits plan costs are diabetes, autoimmune diseases (excluding diabetes), mental health, lung disorders/respiratory and cardiovascular and […]
U.S. employers’ health benefits costs are expected to increase to nearly eight per cent for 2025, the highest amount in more than a decade, according to a new survey by Business Group on Health. The survey, which polled 125 large employers, found they’re planning to continue to absorb much of the increases at least for […]